¼¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°Á "ºÎÀÎÁ¾¾çÇÐ" : 2019-12-15 |
|
¼¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°Á "ºÎÀÎÁ¾¾çÇÐ" : 2019-12-15 ±³À°ÀÏÀÚ : 2019-12-15 ±³À°Àå¼Ò : ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç ±³À°ÁÖÁ¦ : ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°Á "ºÎÀÎÁ¾¾çÇÐ" ÁÖÃÖ±â°ü : ¼¿ï´ëÇб³º´¿ø ½ÃÇà±â°ü(ÁöºÎ/°ú) : »êºÎÀΰú ´ã´çÀÚ : ÀÓÇö¿µ ¿¬¶ôó : 02-2072-2388 À̸ÞÀÏ : hyrimobgy@nate.com ±³À°Á¾·ù : »êºÎÀΰúÀÇ»çÇÐ, ÀÇÇб³À° Âü¼®¿¹»óÀοø : 160¸í Èñ¸ÁÆòÁ¡ : 4Á¡ Áö¿ª : ¼¿ïƯº°½Ã ±³À°½Ã°£ : 4 ½Ã°£ 30ºÐ ¼¼ºÎ¼ö°·á : 50,000¿ø ºñ°í ±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 13:00~13:20 Endometrial cancer Á¤ÇöÈÆ(¼¿ïÀÇ´ë) ±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 13:20~13:40 Ovarian cancer À̸¶¸®¾Æ(¼¿ïÀÇ´ë) ±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 13:40~14:00 Risk reducing strategies ¼µ¿ÈÆ(¼¿ïÀÇ´ë) Åä·Ð 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 14:00~14:15 Discussion () ±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 14:15~14:35 Minimally invasive surgery after LACC trial ³ëÀçÈ«(¼¿ïÀÇ´ë) ±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 14:35~14:55 Hyperthermic intraperitoneal chemotherapy ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ) ±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 14:55~15:15 Role of lymphadenectomy in gynecologic cancers ±èÅÂÈÆ(¼¿ïÀÇ´ë) Åä·Ð 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 15:15~15:30 Discussion () ÈÞ½Ä 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 15:30~15:50 Coffee Break () ±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 15:50~16:10 Bevacizumab ¹èÀ縸(ÇѾçÀÇ´ë) ±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 16:10~16:30 PARP inhibitors ÀÌäÇü(µ¿±¹ÀÇ´ë) ±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 16:30~16:50 Immune checkpoint inhibitors ±èÈñ½Â(¼¿ïÀÇ´ë) Åä·Ð 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 16:50~17:00 Discussion () ±³À°½Ã°£ 12-15 ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ´ë°´ç 17:00~17:40 ¹«¾ùÀÌ ÃÖ¼±Àϱî? »êºÎÀΰú ÀÇ»ç·Î »ì¾Æ°¡±â ¼ÛÇöÁø(ºÎõ¼¿ï¿©¼ºº´¿ø) ±³À°½Ã°£ 12-15 17:40~17:50 ¸ÎÀ½¸» () |
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|
Á¦¸ñ |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 54 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,529 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 49 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 60 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 107 , ´ñ±Û¼ö : 0 |